---
title: Geriatric Assessments in Elderly Diffuse Large B-cell Lymphoma
nct_id: NCT02555267
overall_status: COMPLETED
sponsor: Chonbuk National University Hospital
study_type: OBSERVATIONAL
primary_condition: Lymphoma, Large B-cell, Diffuse
countries: South Korea
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02555267.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02555267"
ct_last_update_post_date: 2023-02-03
last_seen_at: "2026-05-12T07:19:25.785Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Geriatric Assessments in Elderly Diffuse Large B-cell Lymphoma

**Official Title:** Multi-center, Prospective Cohort Study to Investigate the Impact of Comprehensive Geriatric Assessments on Survival and Toxicities in Elderly Diffuse Large B-cell Lymphoma Patients Treated With R-CHOP

**NCT ID:** [NCT02555267](https://clinicaltrials.gov/study/NCT02555267)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 148
- **Lead Sponsor:** Chonbuk National University Hospital
- **Collaborators:** The Catholic University of Korea, Kyungpook National University Hospital, Keimyung University Dongsan Medical Center, Korea University Anam Hospital, Korea University Guro Hospital, Kosin University Gospel Hospital, Pusan National University Hospital, Soonchunhyang University Hospital, Ajou University School of Medicine, Chonnam National University Hospital
- **Conditions:** Lymphoma, Large B-cell, Diffuse
- **Start Date:** 2015-09
- **Completion Date:** 2020-12
- **CT.gov Last Update:** 2023-02-03

## Brief Summary

This study investigate the impact of comprehensive geriatric assessments using activity of daily living (ADL), instrumental activity of daily living (IADL), and Charlson's comorbidity index (CCI) on survival and toxicities in Korean patients with diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP.

## Eligibility

- **Minimum age:** 65 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Patients with newly diagnosed CD20+ DLBCL
* 65 years old or over
* Scheduled to receive R-CHOP chemotherapy
* Informed consent

Exclusion Criteria:

* Other histology than CD20+ DLBCL
* Primary central nervous system DLBCL
* Patients with a diagnosis of cancer (other than basal or squamous cell carcinoma of the skin, cervical carcinoma in situ, well differentiated thyroid cancer \[papillary or follicular thyroid cancer\]) within 3 years before the study entry or with any treatment for cancer within 3 years before entry
* Consent withdrawal
```

## Arms

- **Elderly patients with DLBCL** — Elderly patients (age\>=65 years) with DLBCL treated with R-CHOP chemotherapy

## Primary Outcomes

- **Event-free survival** _(time frame: 2 years)_ — Event-free survival was defined as death, relapse from complete remission, progression during or after treatment, and discontinuation or changes of therapy during treatments

## Secondary Outcomes

- **Overall survival** _(time frame: 5 years)_
- **Progression-free survival** _(time frame: 5 years)_
- **Cumulative incidence of grade 3/4 adverse events and premature treatment discontinuation** _(time frame: 1 year)_

## Locations (1)

- Chonbuk National University Hospital, Jeonju, South Korea

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.chonbuk national university hospital|jeonju||south korea` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT02555267.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT02555267*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*